GILD Live signals | Maximize Profits with Getagraph.com

BUY 818 min ago

@ $67.33

Issued: 22 Apr 2024 @ 14:46

Return: -0.56%

Previous signal: Apr 19 - 14:07

Previous signal: Sell

Return: 1.32 %

Live Chart Being Loaded With Signals

Commentary (22 Apr 2024 @ 16:00):

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally...

Stats
Today's Volume	5.56M
Average Volume	7.26M
Market Cap	83.48B
EPS	$0 ( 2024-02-06 )
Next earnings date	( $1.030 ) 2024-04-25
Last Dividend	$0.750 ( 2023-12-14 )
Next Dividend	$0 ( N/A )
P/E	14.88
ATR14	$0.820 (1.23%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Parsey Merdad	Sell	2 000	Common Stock
2024-03-28	Lofton Kevin E	Buy	34	Phantom Stock
2024-03-10	Telman Deborah H	Buy	54 980	Non-qualified Stock Option (Right to Buy)
2024-03-10	Telman Deborah H	Buy	10 815	Restricted Stock Unit
2024-03-10	Telman Deborah H	Sell	2 555	Restricted Stock Unit

INSIDER POWER
62.18
Last 99 transactions
Buy: 1 293 767 \| Sell: 311 296

Volume Correlation

Long: -0.96 (very strong negative)

Short: -0.39 (neutral)

Signal:(32) Neutral

Gilead Sciences Inc Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Gilead Sciences Inc Correlation - Currency/Commodity

-0.88
( strong negative )

-0.89
( strong negative )

0.00
( neutral )

-0.69
( moderate negative )

-0.05
( neutral )

-0.06
( neutral )

Gilead Sciences Inc Financials

Annual	2023
Revenue:	$27.12B
Gross Profit:	$21.15B (77.99 %)
EPS:	$4.54

Q4	2023
Revenue:	$7.12B
Gross Profit:	$5.56B (78.07 %)
EPS:	$1.150

Q3	2023
Revenue:	$7.05B
Gross Profit:	$5.49B (77.80 %)
EPS:	$1.750

Q2	2023
Revenue:	$6.60B
Gross Profit:	$5.16B (78.15 %)
EPS:	$0.840

Financial Reports:

No articles found.

Gilead Sciences Inc Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0.730 (N/A)	$0.730 (N/A)	$0.750 (N/A)	$0.750 (N/A)	$0.750 (N/A)	$0.750 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Gilead Sciences Inc Dividend Information - Dividend King

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 5.41 - Stable (8.25%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.430	2015-06-12
Last Dividend	$0.750	2023-12-14
Next Dividend	$0	N/A
Payout Date	2023-12-28
Next Payout Date	N/A
# dividends	35	--
Total Paid Out	$21.49	--
Avg. Dividend % Per Year	2.65%	--
Score	5.3	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	5.41
Div. Directional Score	7.98	--

Next Divdend (Est)
(2024-07-01)

$0.764 Estimate 39.70 %

Dividend Stability

0.79 Good

Dividend Score

5.30

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
2015	$1.290	1.36%
2016	$1.840	1.88%
2017	$2.08	2.80%
2018	$2.28	3.08%
2019	$2.52	3.97%
2020	$2.72	4.17%
2021	$2.84	4.72%
2022	$2.92	4.02%
2023	$3.00	3.51%
2024	$0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.209	1.500	5.82	8.73	[0 - 0.5]
returnOnAssetsTTM	0.0912	1.200	6.96	8.35	[0 - 0.3]
returnOnEquityTTM	0.260	1.500	8.22	10.00	[0.1 - 1]
payoutRatioTTM	0.672	-1.000	3.28	-3.28	[0 - 1]
currentRatioTTM	1.459	0.800	7.71	6.17	[1 - 3]
quickRatioTTM	1.057	0.800	8.49	6.79	[0.8 - 2.5]
cashRatioTTM	0.539	1.500	8.11	10.00	[0.2 - 2]
debtRatioTTM	0.402	-1.500	3.30	-4.94	[0 - 0.6]
interestCoverageTTM	9.00	1.000	7.78	7.78	[3 - 30]
operatingCashFlowPerShareTTM	6.42	2.00	7.86	10.00	[0 - 30]
freeCashFlowPerShareTTM	5.95	2.00	7.03	10.00	[0 - 20]
debtEquityRatioTTM	1.098	-1.500	5.61	-8.41	[0 - 2.5]
grossProfitMarginTTM	0.780	1.000	0.335	0.335	[0.2 - 0.8]
operatingProfitMarginTTM	0.313	1.000	5.73	5.73	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.320	1.000	9.33	9.33	[0.2 - 2]
assetTurnoverTTM	0.436	0.800	-0.424	-0.339	[0.5 - 2]
Total Score				10.55

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	15.01	1.000	8.58	0	[1 - 100]
returnOnEquityTTM	0.260	2.50	8.85	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	5.95	2.00	8.02	10.00	[0 - 30]
dividendYielPercentageTTM	4.43	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	6.42	2.00	7.86	10.00	[0 - 30]
payoutRatioTTM	0.672	1.500	3.28	-3.28	[0 - 1]
pegRatioTTM	0.0508	1.500	-2.99	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.295	1.000	5.12	0	[0.1 - 0.5]
Total Score				5.41

Gilead Sciences Inc

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.

Realtime updates for Gilead Sciences Inc [GILD]

Upcoming Earnings Alert

Gilead Sciences Inc Dividend Information - Dividend King

Dividend Commentary

Top 10 dividend Companies for NASDAQ

Dividend Sustainability Score (DSS)

Dividend Growth Score (DGS)